---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-001200"
form_type: "8-K"
ticker: "BNGO"
cik: "0001411690"
company_name: "Bionano Genomics, Inc."
filed_at: "2024-01-08T23:59:59+00:00"
generated_at: "2026-06-07T02:08:28.578599+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Bionano prelim Q4 rev $10.4-10.7M (+27-30% YoY); OGM base 326 (+36%)

## Summary
- Prelim Q4 2023 rev $10.4-10.7M vs $8.2M Q4 2022; FY rev $35.8-36.1M (+29-30%).
- OGM installed base 326 as of year-end 2023, up 36% from 240 in 2022.
- Q4 flowcell sales 7,980, up 67% from 4,781 in Q4 2022.
- Cash, equivalents & securities ~$102.8M at Dec 31, 2023; $36.1M restricted.
- Raised net $11.0M from ATM in Nov-Dec 2023 and $2.9M additional in Jan 2024.

## SEC filing metadata
- accession: 0001140361-24-001200
- form_type: 8-K
- ticker: BNGO
- cik: 0001411690
- company_name: Bionano Genomics, Inc.
- filed_at: 2024-01-08T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1411690/000114036124001200/0001140361-24-001200-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1411690/000114036124001200/ef20018237_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-001200
- JSON: https://secwatch.observer/filing/0001140361-24-001200.json
- Plain text: https://secwatch.observer/filing/0001140361-24-001200.txt

## Key facts
- Earnings Releases
  Bionano Genomics, Inc. reported the fourth quarter of 2023 results: revenue in the range of $10.4 million to $10.7 million.
  - Period: the fourth quarter of 2023
  - Revenue: in the range of $10.4 million to $10.7 million
  - Result: preliminary results
  source text: Revenues for the fourth quarter 2023 are expected to be in the range of $10.4 million to $10.7 million, an estimated increase of 27% to 30% compared to $8.2 million in the fourth quarter of 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1411690/000114036124001200/0001140361-24-001200-index.htm
- Earnings Releases
  Bionano Genomics, Inc. reported the fiscal year ended December 31, 2023 results: revenue in the range of $35.8 million and $36.1 million.
  - Period: the fiscal year ended December 31, 2023
  - Revenue: in the range of $35.8 million and $36.1 million
  - Result: preliminary results
  source text: Full year 2023 revenue is expected to be in the range of $35.8 million and $36.1 million, an estimated increase of 29% to 30% compared to full year 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1411690/000114036124001200/0001140361-24-001200-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.